MA45029B1 - Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer - Google Patents

Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer

Info

Publication number
MA45029B1
MA45029B1 MA45029A MA45029A MA45029B1 MA 45029 B1 MA45029 B1 MA 45029B1 MA 45029 A MA45029 A MA 45029A MA 45029 A MA45029 A MA 45029A MA 45029 B1 MA45029 B1 MA 45029B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
lag3 antibodies
relates
lag3
antibody molecules
Prior art date
Application number
MA45029A
Other languages
English (en)
French (fr)
Other versions
MA45029A (fr
Inventor
Lukasz Chlewicki
Markus Zettl
Ivo Lorenz
Otmar Schaaf
Melanie Wurm
Jean-François Fortin
Scott Brodeur
Keith A Canada
Pankaj Gupta
Priyanka Gupta
Rocio K Perez
Jr Joseph Robert Woska
Haiguang Xiao
Danlin Yang
Walter Carroll Davidson
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA45029A publication Critical patent/MA45029A/fr
Publication of MA45029B1 publication Critical patent/MA45029B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA45029A 2016-05-18 2017-05-17 Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer MA45029B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170174 2016-05-18
PCT/EP2017/061901 WO2017198741A1 (en) 2016-05-18 2017-05-17 Anti pd-1 and anti-lag3 antibodies for cancer treatment

Publications (2)

Publication Number Publication Date
MA45029A MA45029A (fr) 2019-03-27
MA45029B1 true MA45029B1 (fr) 2021-03-31

Family

ID=56014918

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055697A MA55697A (fr) 2016-05-18 2017-05-17 Molécules d'anticorps pour le traitement du cancer
MA45029A MA45029B1 (fr) 2016-05-18 2017-05-17 Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055697A MA55697A (fr) 2016-05-18 2017-05-17 Molécules d'anticorps pour le traitement du cancer

Country Status (30)

Country Link
US (3) US11028169B2 (OSRAM)
EP (2) EP3848393A1 (OSRAM)
JP (3) JP6585860B2 (OSRAM)
KR (2) KR20220103806A (OSRAM)
CN (2) CN109415439B (OSRAM)
AR (1) AR108516A1 (OSRAM)
AU (1) AU2017266298B2 (OSRAM)
CA (1) CA3020649A1 (OSRAM)
CL (2) CL2018003153A1 (OSRAM)
CO (1) CO2018012374A2 (OSRAM)
CY (1) CY1123977T1 (OSRAM)
DK (1) DK3458478T3 (OSRAM)
EA (1) EA201892616A1 (OSRAM)
ES (1) ES2857813T3 (OSRAM)
HU (1) HUE053452T2 (OSRAM)
IL (1) IL262892B2 (OSRAM)
LT (1) LT3458478T (OSRAM)
MA (2) MA55697A (OSRAM)
MX (2) MX393609B (OSRAM)
MY (1) MY193112A (OSRAM)
PE (1) PE20190108A1 (OSRAM)
PH (1) PH12018502429A1 (OSRAM)
PL (1) PL3458478T3 (OSRAM)
RS (1) RS61510B1 (OSRAM)
SA (1) SA518400424B1 (OSRAM)
SG (1) SG11201809627QA (OSRAM)
SI (1) SI3458478T1 (OSRAM)
TW (2) TWI762484B (OSRAM)
UA (1) UA127200C2 (OSRAM)
WO (1) WO2017198741A1 (OSRAM)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
AR108516A1 (es) 2016-05-18 2018-08-29 Boehringer Ingelheim Int Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
CN110214153B (zh) 2016-11-18 2024-03-29 法国施维雅药厂 抗pd-1抗体及组合物
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
IL313695A (en) 2017-02-10 2024-08-01 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
JP2020516604A (ja) * 2017-04-05 2020-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん併用療法
US11939380B2 (en) * 2017-04-05 2024-03-26 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
HUE065242T2 (hu) 2017-05-30 2024-05-28 Bristol Myers Squibb Co LAG-3-pozitív tumorok kezelése
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
CN118356488A (zh) 2017-05-30 2024-07-19 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
TWI869334B (zh) * 2017-12-22 2025-01-11 大陸商江蘇恆瑞醫藥股份有限公司 一種ｌａｇ-３抗體醫藥組成物及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
WO2019165195A1 (en) * 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN120943884A (zh) 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
MX2020011176A (es) 2018-05-07 2020-11-12 Genmab As Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN119185533A (zh) * 2018-06-11 2024-12-27 耶鲁大学 新型免疫检查点抑制剂
US20210238287A1 (en) 2018-07-26 2021-08-05 Bristol-Myers Squibb Company LAG-3 Combination Therapy for the Treatment of Cancer
PL3866850T3 (pl) 2018-10-19 2024-10-14 Bristol-Myers Squibb Company Terapia skojarzona czerniaka
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3880709A4 (en) * 2018-11-05 2022-07-27 Merck Sharp & Dohme Corp. DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
US20210380694A1 (en) 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CN113646048A (zh) * 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法
EP3947455A1 (en) * 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy
WO2020206169A1 (en) 2019-04-02 2020-10-08 Kupper Thomas S Methods for identifying progression of a primary melanoma
SG11202111262XA (en) * 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114008080B (zh) * 2019-06-12 2023-06-09 南京金斯瑞生物科技有限公司 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
CN112121169B (zh) * 2019-06-24 2023-10-24 广州再极医药科技有限公司 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
TWI889320B (zh) 2019-07-05 2025-07-01 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
BR112022000247A2 (pt) 2019-07-09 2022-02-22 Cadila Healthcare Ltd Anticorpo ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor, célula hospedeira e combinação
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TW202120550A (zh) 2019-08-08 2021-06-01 日商小野藥品工業股份有限公司 雙特異性蛋白質
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
BR112022001985A2 (pt) * 2019-09-11 2022-05-10 Boehringer Ingelheim Io Canada Inc Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina
EP4031873A1 (en) 2019-09-22 2022-07-27 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
KR20220139915A (ko) 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
WO2021245111A1 (en) 2020-06-03 2021-12-09 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
CN111808192B (zh) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 结合lag3的抗体及其用途
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
US20230265188A1 (en) 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
AR123585A1 (es) 2020-09-24 2022-12-21 Merck Sharp & Dohme Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y métodos de uso de las mismas
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
JP2023549581A (ja) 2020-11-17 2023-11-27 シージェン インコーポレイテッド ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
HRP20250628T1 (hr) 2020-12-28 2025-07-18 Bristol-Myers Squibb Company Mješavine antitijela i postupci njihove upotrebe
JP2024506839A (ja) 2021-01-29 2024-02-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キナーゼ阻害剤を用いてがんを処置する方法
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
US20240279225A1 (en) 2021-04-08 2024-08-22 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20240417473A1 (en) 2021-10-29 2024-12-19 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
AU2023213937A1 (en) 2022-01-26 2024-07-18 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
IL314713A (en) 2022-02-25 2024-10-01 Bristol Myers Squibb Co Combined therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
JP2025508076A (ja) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
US20250270318A1 (en) * 2022-03-21 2025-08-28 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2025523031A (ja) 2022-07-15 2025-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための結合性分子
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
EP4626552A1 (en) 2022-12-01 2025-10-08 MedImmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
CN121002071A (zh) 2023-01-20 2025-11-21 勃林格殷格翰国际有限公司 IL-12 Fc融合蛋白
EP4665410A1 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
AU2024271605A1 (en) 2023-05-12 2025-11-13 BioNTech SE Antibodies capable of binding to ox40, variants thereof and uses thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
TW202535926A (zh) 2023-10-30 2025-09-16 美商再生元醫藥公司 穩定抗體配製物
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025132695A1 (en) 2023-12-19 2025-06-26 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a gasdermin
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
KR101937733B1 (ko) 2012-05-24 2019-01-11 마운트게이트 그룹 리미티드 광견병 감염의 방지 및 치료에 관한 조성물 및 방법
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2808654T3 (es) * 2013-03-15 2021-03-01 Glaxosmithkline Ip Dev Ltd Proteínas de unión anti-LAG-3
HRP20210122T1 (hr) * 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
KR20210141789A (ko) * 2013-09-20 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
JP6535337B2 (ja) * 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PH12016501545B1 (en) * 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
US11661462B2 (en) * 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HUE050894T2 (hu) 2015-04-17 2021-01-28 Bristol Myers Squibb Co Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
AR108516A1 (es) 2016-05-18 2018-08-29 Boehringer Ingelheim Int Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer

Also Published As

Publication number Publication date
SA518400424B1 (ar) 2022-08-17
US20240124581A1 (en) 2024-04-18
PE20190108A1 (es) 2019-01-15
EP3458478B1 (en) 2021-01-06
MX393609B (es) 2025-03-24
US20210095020A1 (en) 2021-04-01
KR20190006177A (ko) 2019-01-17
TW201806974A (zh) 2018-03-01
IL262892B2 (en) 2024-04-01
CA3020649A1 (en) 2017-11-23
EP3848393A1 (en) 2021-07-14
SI3458478T1 (sl) 2021-04-30
DK3458478T3 (da) 2021-03-22
EA201892616A1 (ru) 2019-05-31
MX2022008184A (es) 2022-08-02
US11028169B2 (en) 2021-06-08
KR20220103806A (ko) 2022-07-22
US11795219B2 (en) 2023-10-24
CL2021002094A1 (es) 2022-04-08
CY1123977T1 (el) 2022-05-27
IL262892B1 (en) 2023-12-01
SG11201809627QA (en) 2018-12-28
PL3458478T3 (pl) 2021-06-28
AU2017266298B2 (en) 2024-01-04
PH12018502429A1 (en) 2019-09-30
IL262892A (en) 2018-12-31
US20170334995A1 (en) 2017-11-23
KR102419412B1 (ko) 2022-07-12
NZ746845A (en) 2025-02-28
AR108516A1 (es) 2018-08-29
CO2018012374A2 (es) 2018-11-30
RS61510B1 (sr) 2021-03-31
TWI762484B (zh) 2022-05-01
TW202307002A (zh) 2023-02-16
JP2020007340A (ja) 2020-01-16
JP6585860B2 (ja) 2019-10-02
JP2019522460A (ja) 2019-08-15
HUE053452T2 (hu) 2021-07-28
BR112018072986A2 (pt) 2019-03-06
CN109415439B (zh) 2022-10-04
MY193112A (en) 2022-09-26
CN115340608A (zh) 2022-11-15
AU2017266298A1 (en) 2018-10-25
MA55697A (fr) 2022-02-23
JP6585801B2 (ja) 2019-10-02
CN109415439A (zh) 2019-03-01
CL2018003153A1 (es) 2019-01-18
EP3458478A1 (en) 2019-03-27
LT3458478T (lt) 2021-02-10
UA127200C2 (uk) 2023-06-07
ES2857813T3 (es) 2021-09-29
WO2017198741A1 (en) 2017-11-23
MA45029A (fr) 2019-03-27
MX2018014102A (es) 2019-04-29
JP2019050804A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
WO2018069500A3 (en) Anti-lag-3 antibodies and compositions
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
MA51844A (fr) Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA40132B1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA38478A1 (fr) Anticorps anti-pac1 humains
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
SA523440622B1 (ar) أجسام مضادة
MA39342B2 (fr) Anticorps il -21
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.